{
  "abstract": "Psoriasis is a chronic inflammatory skin disease marked by epidermal hyperplasia and distinct metabolic alterations. Here, we investigated the metabolic impact of targeting translation initiation factors by performing 1H NMR-based metabolomic profiling on polar skin extracts from imiquimod-induced (IMQ) and K5.TGF{beta}1 transgenic (TGF{beta}) mouse models treated with eIF1A or eIF3B siRNA. IMQ-treated skin demonstrated significant, human-like metabolic shifts, including depleted energy substrates (glucose, glycogen, 3-hydroxybutyrate) and elevated phospholipid/nucleotide markers, which correlated strongly with epidermal thickness. In contrast, TGF{beta} skin exhibited no broad baseline polar metabolome changes. eIF1A/eIF3B inhibition selectively attenuated IMQ-associated energy and phospholipid alterations without causing widespread metabolic disruption in TGF{beta} skin. Overall, eIF1A/eIF3B inhibition ameliorated psoriasis-like pathology and mitigated disease-associated metabolic demands in a context-dependent manner.",
  "abstract_shown": true,
  "affiliations": [
    "Medical University of Graz, Department of Dermatology and Venereology, Graz, Austria."
  ],
  "article_type": "New results",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "name": "N. Bordag"
    },
    {
      "name": "B. M. R. Bourgeois"
    },
    {
      "name": "T. Madl"
    },
    {
      "name": "P. Wolf"
    },
    {
      "affs": [
        0
      ],
      "name": "N. Golob-Schwarzl"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1q4sstjm99cq6.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.10.08.757342",
  "fulltext_url": "https://www.biorxiv.org/content/10.64898/2026.10.08.757342v1.full",
  "id": "1q4sstjm99cq6",
  "issns": [],
  "landing_url": "https://www.biorxiv.org/content/10.64898/2026.10.08.757342v1",
  "language": null,
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "biorxiv",
      "molecular biology"
    ],
    [
      "openalex",
      "2403|Psoriasis: Treatment and Pathogenesis"
    ]
  ],
  "openalex": "W7221850705",
  "pdf_url": "https://www.biorxiv.org/content/10.64898/2026.10.08.757342v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-08",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/1q4sstjm99cq6.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:27:59Z",
      "native_id": "10.64898/2026.10.08.757342",
      "source": "biorxiv",
      "url": "https://www.biorxiv.org/content/10.64898/2026.10.08.757342v1"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "biorxiv:molecular biology",
      "subfield": "molecular-biology"
    }
  ],
  "title": "A metabolic perspective on eIF1A and eIF3B inhibition as a potential therapeutic strategy in psoriasis",
  "title_text": "A metabolic perspective on eIF1A and eIF3B inhibition as a potential therapeutic strategy in psoriasis",
  "type": "preprint",
  "updated_at": "2026-10-30T12:27:59Z",
  "url": "https://research.draconitic.com/paper/1q4sstjm99cq6",
  "venue": "bioRxiv",
  "versions": []
}